Suppr超能文献

碳酸酐酶 IX 不是非转移性透明细胞肾细胞癌预后的预测因子——组织微阵列的数字分析。

Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.

机构信息

Laboratory of Medical Investigation (LIM55), Urology Department, University of Sao Paulo Medical School and Uro-Oncology Group, Urology Department, University of Sao Paulo Medical School, Sao Paulo, Brazil.

出版信息

Int Braz J Urol. 2013 Jul-Aug;39(4):484-92. doi: 10.1590/S1677-5538.IBJU.2013.04.05.

Abstract

INTRODUCTION

The knowledge about the molecular biology of clear cell renal cell carcinoma (ccRCC) is evolving, and Carbonic Anhydrase type IX (CA-IX) has emerged as a potential prognostic marker in this challenging disease. However, most of the literature about CA-IX on ccRCC comes from series on metastatic cancer, with a lack of series on non-metastatic cancer. The objective is to evaluate the expression of CA-IX in a cohort of non-metastatic ccRCC, correlating with 1) overall survival, and 2) with established prognostic parameters (T stage, tumor size, Fuhrman nuclear grade, microvascular invasion and peri-renal fat invasion).

MATERIALS AND METHODS

This is a retrospective cohort study. We evaluated 95 patients with non-metastatic clear cell renal cell carcinoma, as to the expression of CA-IX. The analyzed parameters where: overall survival (OS), TNM stage, tumor size (TS), Fuhrman nuclear grade (FNG), microvascular invasion (MVI), peri-renal fat invasion (PFI). We utilized a custom built tissue microarray, and the immunoexpression was digitally quantified using the Photoshop ® software.

RESULTS

The mean follow-up time was 7.9 years (range 1.9 to 19.5 years). The analysis of CA-IX expression against the selected prognostic parameters showed no correlation. The results are as follows: Overall survival (p = 0.790); T stage (p = 0.179); tumor size (p = 0.143); grouped Fuhrman nuclear grade (p = 0.598); microvascular invasion (p = 0.685), and peri-renal fat invasion (p = 0.104).

CONCLUSION

Carbonic anhydrase type IX expression does not correlate with overall survival and conventional prognostic parameters in non-metastatic clear cell renal cell carcinoma.

摘要

介绍

透明细胞肾细胞癌(ccRCC)的分子生物学知识正在不断发展,碳酸酐酶 IX(CA-IX)已成为该挑战性疾病中一种有潜力的预后标志物。然而,关于 ccRCC 中 CA-IX 的大多数文献来自转移性癌症的系列研究,缺乏非转移性癌症的系列研究。本研究旨在评估 CA-IX 在非转移性 ccRCC 队列中的表达情况,并与 1)总体生存率和 2)与既定预后参数(T 分期、肿瘤大小、Fuhrman 核分级、微血管侵犯和肾周脂肪侵犯)相关联。

材料和方法

这是一项回顾性队列研究。我们评估了 95 例非转移性透明细胞肾细胞癌患者的 CA-IX 表达情况。分析的参数包括:总体生存率(OS)、TNM 分期、肿瘤大小(TS)、Fuhrman 核分级(FNG)、微血管侵犯(MVI)、肾周脂肪侵犯(PFI)。我们使用了定制的组织微阵列,并用 Photoshop®软件对免疫表达进行数字化定量。

结果

平均随访时间为 7.9 年(范围 1.9 至 19.5 年)。CA-IX 表达与所选预后参数的分析显示无相关性。结果如下:总体生存率(p = 0.790);T 分期(p = 0.179);肿瘤大小(p = 0.143);分组 Fuhrman 核分级(p = 0.598);微血管侵犯(p = 0.685)和肾周脂肪侵犯(p = 0.104)。

结论

在非转移性透明细胞肾细胞癌中,碳酸酐酶 IX 表达与总体生存率和传统预后参数无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验